DT‐678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y(12) antagonists

The novel clopidogrel conjugate, DT‐678, is an effective inhibitor of platelets and thrombosis in preclinical studies. However, a comparison of the bleeding risk with DT‐678 and currently approved P2Y(12) antagonists has yet to be determined. The objective of this study was to evaluate the bleeding...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauver, Dale A., Kuszynski, Dawn S., Christian, Barbara D., Bernard, Matthew P., Teuber, James P., Markham, Bruce E., Chen, Yuqing E., Zhang, Haoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658415/
https://www.ncbi.nlm.nih.gov/pubmed/31372229
http://dx.doi.org/10.1002/prp2.509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658415/
https://www.ncbi.nlm.nih.gov/pubmed/31372229
http://dx.doi.org/10.1002/prp2.509

Ejemplares similares